Compare BWXT & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWXT | GMAB |
|---|---|---|
| Founded | 1867 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | 3029 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 16.9B |
| IPO Year | 2010 | N/A |
| Metric | BWXT | GMAB |
|---|---|---|
| Price | $217.47 | $26.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $209.70 | $39.56 |
| AVG Volume (30 Days) | 857.5K | ★ 1.5M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.52% | N/A |
| EPS Growth | ★ 16.61 | N/A |
| EPS | ★ 3.58 | N/A |
| Revenue | ★ $1,687,738,000.00 | N/A |
| Revenue This Year | $20.47 | $17.85 |
| Revenue Next Year | $9.50 | $16.04 |
| P/E Ratio | $60.22 | ★ $1.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $102.42 | $18.89 |
| 52 Week High | $241.82 | $35.43 |
| Indicator | BWXT | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 42.18 |
| Support Level | $187.96 | $24.95 |
| Resistance Level | $219.10 | $29.64 |
| Average True Range (ATR) | 8.61 | 0.55 |
| MACD | -2.32 | -0.16 |
| Stochastic Oscillator | 30.22 | 20.89 |
BWX Technologies Inc is a specialty manufacturer and service provider of nuclear components, operating in two segments: Government Operations and Commercial Operations. The Government Operations segment produces naval nuclear reactors and fuel for the U.S. Naval Nuclear Propulsion Program, while the Commercial Operations segment designs and manufactures commercial nuclear steam generators, heat exchangers, pressure vessels, reactor components, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level nuclear waste. The majority of the company's revenue comes from Government Operations, with sales principally in the United States, Canada, and other regions.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.